Johns Hopkins School of Medicine
Baltimore, Maryland, 21205, United States
Location status: Recruiting
NCT Number: NCT05151562
This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD).
60 patients with MCI or mild dementia due to AD will receive two 30 minutes reminiscence-targeted virtual music therapy interventions per week for 8 weeks (a total of 16 sessions).
Participants' (or supported by the study partner) self-reported and measurable outcomes including cognitive, anxiety, quality of life, and autobiographical memory will be assessed before and after the 8-week course of treatment. Blood-oxygenation level-dependent (BOLD) in functional magnetic resonance imaging (fMRI) will also be also measured before and after the 8-week course of treatment.
Interested in participating?
Request Info18 year–89 year
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21205, United States
Location status: Recruiting
Despite advancements in mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) treatment, patients who live with these symptoms still have many unmet neuropsychiatric needs. In investigating holistic approaches to treatment generally, it is important to utilize non-pharmacological interventions.
Kelly and Ahessy implemented reminiscence-focused group music therapy to promote positive mood and engagement through musical expression (e.g. singing, moving, body percussion) and verbal interaction, using thematic sessions that reflected the music preferences of the participants. The researchers found that a balance of familiar structures, such as greeting and ending songs, paired with adaptability on behalf of the music facilitator created meaningful space for reminiscence and shared engagement. The researchers also identify music as a core element that facilitated the sharing musical and extramusical personal memories, as well as provided grounding and opportunities for re-connection during moments of disorientation within the group.
Although use of virtual music therapy due to COVID-19 has been increased, the impact of virtual music therapy sessions on reminiscence is minimally explored in the literature. A clear benefit of virtual music therapy is increased access to care for participants living in rural areas or for whom travel is difficult, enabling participation in meaningful interventions without disrupting daily routines. Additionally, the ability to engage in music therapy from the familiarity of one's own home has been shown to facilitate relationship development between patients with dementia and the patients' caregivers, as well as increase feelings of comfort and relaxation.
The present study seeks to expand upon previous work by adding a layer of personalization and engagement. Rather than simply assigning individuals a regimen of music listening, the investigators will engage participants in regularly occurring virtual music therapy sessions centered on playing familiar songs live and stimulating reminiscence through autobiographical conversation. Such a study offers several advantages over previous similar studies' formats as it (a) allows researchers to maintain maximum control over how the treatment is administered, (b) saves participants and caregivers the stress of traveling for therapy (especially pertinent given the study's older demographic), (c) allows participants autonomy over when and where the participants engage in therapy, likely from the comfort of home, and (d) provides opportunities for music therapy to become a meaningful twice-weekly routine for both participants and the participants' care partners. Appreciating music is far greater than simply listening to it, and this study seeks to utilize the transformative power of individualized live music therapy interventions.
Participants with MCI or mild dementia due to AD will attend 30-minute reminiscence-targeted virtual music therapy during an 8 week, twice-weekly course of music therapy (a total of 16 sessions) through a Zoom. Participants' cognitive, anxiety, quality of life, and autobiographical memory level will be measured pre- and post- 16 virtual music therapy sessions. Brain activation patterns using functional magnetic resonance imaging (fMRI) will be compared before and after virtual music therapy sessions to understand if individualized virtual music therapy sessions can change cortical activity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
Time frame: Baseline and Post-test Week 12
AMT is used to assess the degree of specificity of autobiographical memory. The AMT usually contains cue words of both positive and negative valence, but it is unclear whether these valences form separate factors or not. Participants are asked to generate a specific memory that happened on a particular day at least one week ago. The number of specific memories recalled on each AMT is used as the dependent variable, and a higher frequency indicates a greater autobiographical memory level. Scores are on a scale from 1 to 7, where higher scores indicate greater familiarity/imageability.
Time frame: Baseline and Post-test Week 12
The NPI-Q is designed to be a self-administered questionnaire completed by informants about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe; total score range: 0 - 36) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress; total score range: 0-60).
Time frame: Baseline and Post-test Week 12
Blood Oxygen Level dependent (BOLD) signal (in percentage), detected on fMRI, reflects change in deoxyhemoglobin driven by localized changes in brain blood flow and blood oxygenation during music listening. The percentage of change from baseline will be used.
Time frame: Baseline and Post-test Week 12
Montreal Cognitive Assessment (MoCA) is a rapid cognitive screening test that assesses cognitive performance in multiple domains including visuo-spatial and executive functions, naming, memory, attention, language, abstraction, and orientation. Scores on the MoCA range from 0 to 30:
Time frame: Baseline and Post-test Week 12
The QOL-AD is administered in interview format to individuals with dementia. It is a 13-item questionnaire designed to provide both a patient and a caregiver report of the quality of life (QOL). Points are assigned to each item as follows: poor = 1, fair = 2, good = 3, excellent = 4. The total score is the sum of all 13 items.
Time frame: Baseline and Post-test Week 12
SNS is a psychometric instrument that measures human's nostalgia proneness consisting of seven questions that assess a person's attitude towards nostalgia, the degree of experience or tendency to nostalgic feelings and the nostalgia frequency. The score range for each item is from 1 (not at all) to 7 (very much).
Time frame: Baseline and Post-test Week 12
The Spielberger State-Trait Anxiety Inventory (STAI) is a 40-item self-report measure of anxiety using a 4-point Likert-type scale (from 0 to 3 points) for each item. The total score ranges from 0-63. The following guidelines are recommended for the interpretation of scores: 0-9, normal or no anxiety; 10-18, mild to moderate anxiety; 19-29, moderate to severe anxiety; and 30-63, severe anxiety.
Time frame: Baseline and Post-test Week 12
The 15-item geriatric depression scale (GDS-15) is a short form of GDS and is used to screen, diagnose, and evaluate depression in elderly individuals. Most previous studies evaluated the ability of GDS-15 to discriminate between depressive and non-depressive states. Of the 15 items, 10 indicated the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicated depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Time frame: Day 1, Day 3, Day 8, Day 10, Day 15, Day 17, Day 22, Day 24, Day 29, Day 31, Day 36, Day 38, Day 43, Day 45, Day 50, Day 52
The participants will be given a brief reporting form after each virtual music therapy session to generate descriptive data about interventions used most frequently and connected theory (e.g. why participants chose specific interventions during the sessions).
Contact information is provided by the study sponsor or research team.
Alexander Pantelyat, MD
CONTACT
Kyurim Kang, PhD
CONTACT
Johns Hopkins University
Other
Music Therapy for Autobiographical Memory and Neuropsychiatric Symptoms in Alzheimer Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06072963
Alzheimer Disease, Brain Diseases
Ramat Gan, Israel
View Trial DetailsNCT07717567
Alzheimer Disease, Brain Diseases
Milan, Milano, Italy
View Trial DetailsNCT06403345
Alzheimer Disease, Brain Diseases
Bloomington, Indiana, United States
View Trial DetailsNCT05904132
Alzheimer Disease, Brain Diseases
Charlestown, Massachusetts, United States
View Trial Details